Previous 10 | Next 10 |
2024-05-03 01:00:11 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q1 2024 Earnings Call May 02, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q1 2024 Earnings Call Transcript
2024-05-02 11:43:08 ET NovoCure Limited (NVCR) Q1 2024 Earnings Conference Call May 02, 2024 08:00 AM ET Company Participants Ingrid Goldberg - Investor Relations Bill Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Ashley Cordova - Chief F...
2024-05-02 07:51:28 ET More on NovoCure NovoCure: Sell The METIS-Inspired Rally NovoCure Limited (NVCR) Q4 2023 Earnings Call Transcript NovoCure Limited 2023 Q4 - Results - Earnings Call Presentation NovoCure GAAP EPS of -$0.36 beats by $0.06, revenue of $13...
2024-05-02 07:07:02 ET More on NovoCure NovoCure: Sell The METIS-Inspired Rally NovoCure Limited (NVCR) Q4 2023 Earnings Call Transcript NovoCure Limited 2023 Q4 - Results - Earnings Call Presentation NovoCure Q1 2024 Earnings Preview Novocure climbs ...
Use of proceeds to fund working capital needs stemming from Novocure’s anticipated launch in non-small cell lung cancer and settle, upon maturity, Novocure’s convertible notes Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 milli...
Quarterly net revenues of $139 million, up 13% year-over-year, with 3,845 active patients on therapy as of March 31, 2024 Phase 3 METIS trial in brain metastases from non-small cell lung cancer met primary endpoint and will be presented as late-breaking abstract at ASCO 2024 LUNAR...
2024-05-01 11:42:47 ET More on NovoCure NovoCure: Sell The METIS-Inspired Rally NovoCure Limited (NVCR) Q4 2023 Earnings Call Transcript NovoCure Limited 2023 Q4 - Results - Earnings Call Presentation Novocure climbs after late-stage win for lung cancer thera...
2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...
Novocure (NASDAQ: NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from May 31 to June 4. METIS was...
Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego. The presentations, describing preclinical investigations, i...
News, Short Squeeze, Breakout and More Instantly...
2024-08-02 13:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-25 17:30:15 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2024 Earnings Call Jul 25, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2024 Earnings Call Transcript
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ: NVCR) today reported fi...